Ontology highlight
ABSTRACT:
INSTRUMENT(S): Orbitrap Fusion Lumos, Q Exactive HF-X, Orbitrap Exploris 480, Q Exactive HF
ORGANISM(S): Homo Sapiens (human)
TISSUE(S): T-47d Cell, Cell Line Cell
SUBMITTER: Maria Faelth Savitski
LAB HEAD: Marcus Bantscheff
PROVIDER: PXD044331 | Pride | 2025-05-06
REPOSITORIES: Pride
Action | DRS | |||
---|---|---|---|---|
07934_F1_R1_P0283070A01_TMT10.raw.gz | Raw | |||
07934_F1_R1_P0283080A01_TMT10.raw.gz | Raw | |||
F539560.dat | Other | |||
F539596.dat | Other |
Items per page: 1 - 4 of 4 |
Cancer research communications 20240901 9
An in-depth multiomic molecular characterization of PARP inhibitors revealed a distinct poly-pharmacology of niraparib (Zejula) mediated by its interaction with lanosterol synthase (LSS), which is not observed with other PARP inhibitors. Niraparib, in a similar way to the LSS inhibitor Ro-48-8071, induced activation of the 24,25-epoxysterol shunt pathway, which is a regulatory signaling branch of the cholesterol biosynthesis pathway. Interestingly, the combination of an LSS inhibitor with a PARP ...[more]